Hormonal
GLP-1 receptor agonists provide significant cardiovascular risk reduction in both diabetic and non-diabetic patients with established cardiovascular disease, a benefit that is significantly under-recognized by physicians, particularly for non-diabetic patients.
For patients with obesity and established cardiovascular disease, GLP-1 agonists offer significant cardiovascular risk reduction (20% reduction in MACE in non-diabetics). Prescribers should be aware of these benefits to ensure appropriate patient selection and counseling, regardless of diabetic status.
Cardiovascular benefits were perceived by 48.4% of physicians in diabetic patients... and by only 39.3% in nondiabetic patients, significantly below random guessing expectations... Semaglutide and cardiovascular outcomes in obesity without diabetes... 20% reduction in the number of major adverse cardiovascular events
Why this rating
Based on landmark trials (SUSTAIN-6, LEADER, SELECT) with large sample sizes and clear cardiovascular endpoints.
Source
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
Srikanth Krishnan et al. · Journal of Cardiovascular Development and Disease · 2025
DOI 10.3390/jcdd12010019
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →